Journal article
Utility of prognostic genomic tests in breast cancer practice: The impakt 2012 working group consensus statement
JA Azim, S Michiels, F Zagouri, S Delaloge, M Filipits, M Namer, P Neven, WF Symmans, A Thompson, F André, S Loi, C Swanton
Annals of Oncology | Published : 2013
Abstract
Background: We critically evaluated the available evidence on genomic tests in breast cancer to define their prognostic ability and likelihood to determine treatment benefit. Design: Independent evaluation of six genomic tests [Oncotype DxTM, MammaPrint®, Genomic Grade Index, PAM50 (ROR-S), Breast Cancer Index, and EndoPredict] was carried out by a panel of experts in three parameters: analytical validity, clinical validity, and clinical utility based on the principles of the EGAPP criteria. Panel statements: The majority of the working group members found the available evidence on the analytical and clinical validity of Oncotype DxTM and MammaPrint® to be convincing. None of the genomic tes..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
HAA is supported by a translational research grant from the European Society for Medical Oncology (ESMO). FZ is supported by a research grant from the Hellenic Society for Medical Oncology (HeSMO) [grant numbers are not available].